Evaluation of postoperative intratumoral injection of bleomycin for craniopharyngioma in children

Takahashi, Hiroshi; Nakazawa, Shozo; Shimura, Toshiro

doi:10.3171/jns.1985.62.1.0120

Cited by 122 publications

(69 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…74 In cases of cystic craniopharyngiomas, drainage and injection of radioactive isotopes or chemotherapeutic agents, specifically bleomycin, 128 have been reported. Complications of intralesional chemotherapeutic treatment have been reported to be associated with the toxic effects of bleomycin on the hypothalamus, 48 as in a case in which, after intracystic injection of bleomycin, a patient developed hypersomnia, personality changes, memory impairment, and thermal dysfunction.…”

Section: Neurosurg Focus / Volume 12 / May 2002mentioning

confidence: 99%

Tumors of the skull base in children: review of tumor types and management strategies

Tsai¹,

Santoreneos²,

Rutka³

2002

FOC

View full text Add to dashboard Cite

Although many treatment strategies for skull base tumors in adults have been reported, relatively little has been reported regarding such therapies in the pediatric population. Skull base tumors in children present a therapeutic challenge because of their unique pathological composition, the constraints of the maturing skull and brain, and the small size of the patients. In this review, the authors examine the pediatric skull base lesions that occur in the anterior, middle, and posterior cranial base, focusing on unique pediatric tumors such as encepahalocele, fibrous dysplasia, esthesioneuroblastoma, craniopharyngioma, juvenile nasopharyngeal angiofibroma, cholesteatoma, chordoma, chondrosarcoma, and Ewing sarcoma. They review management strategies that include radio- and chemotherapy, as well as surgical approaches with emphasis on the modifications and complications associated with the procedures as they apply in children. Evidence for the advantages and limitations of radiotherapy, chemotherapy, and surgery as it pertains to the pediatric population will be examined. With a working knowledge of skull base anatomy and special considerations of the developing craniofacial skeleton, neurosurgeons can treat skull base lesions in children with acceptable morbidity and mortality rates. Outcomes in this population may be better than those in adults, in part because of the benign histopathology that frequently affects the pediatric skull base, as well as the plasticity of the maturing nervous system.

show abstract

Section: Neurosurg Focus / Volume 12 / May 2002mentioning

confidence: 99%

Tumors of the skull base in children: review of tumor types and management strategies

Tsai¹,

Santoreneos²,

Rutka³

2002

FOC

View full text Add to dashboard Cite

show abstract

“…19 At a mean follow-up of 2 to 7 years (the range of means for the studies), 43 to 70% of patients required no treatment in addition to bleomycin, 5,16,19,33,43 but there is no information about the durability of the bleomycin effect at 10 years or longer. In the Canadian experience, 19 which is similar to the other reported series, 94% responded to intracystic bleomycin, but the duration of response was < 1 year in 47%.…”

Section: Intracystic Bleomycinmentioning

confidence: 99%

“…Takahashi et al 43 first reported the use of intracavitary bleomycin after partial excision of craniopharyngiomas. Subsequently, there have been a number of single-center case series 5,14,16,22,25,27,33,35 and case reports 1,3,9,17,26,41,42 published on the use of intracystic bleomycin for craniopharyngioma, both as de novo treatment and as treatment for recurrences.…”

Section: Intracystic Bleomycinmentioning

confidence: 99%

Intracystic treatments for craniopharyngioma

Steinbok¹,

Hukin

2010

FOC

View full text Add to dashboard Cite

Craniopharyngioma is a benign tumor histopathologically and in theory should be curable by radical resection. In practice, this tumor behaves like a chronic disease, with many issues related to the effect of the tumor itself and the various treatments on the adjacent structures, such as the pituitary stalk and gland, hypothalamus, visual apparatus, and suprasellar arteries. A multimodality approach to the management of these tumors may produce the optimal outcome, balancing disease control and quality of life. In this paper, the role of intracystic therapies is reviewed, with the major focus on intracystic bleomycin and interferon-α.

show abstract

“…Numerous studies have been published on its techniques, indications, and efficacy. 4,5,7,11,12,17,21,[26][27][28] In most studies, brachytherapy is combined with EBR. Previously, we attempted to treat predominantly cystic craniopharyngiomas with brachytherapy alone, withholding external radiation.…”

Section: Efficacy Of Phosphorus-32 Brachytherapy Without External-beamentioning

confidence: 99%

Efficacy of phosphorus-32 brachytherapy without external-beam radiation for long-term tumor control in patients with craniopharyngioma

Ansari¹,

Moore²,

Boaz

et al. 2016

PED

View full text Add to dashboard Cite

OBJECT Radioactive phosphorus-32 (P32) has been used as brachytherapy for craniopharyngiomas with the hope of providing local control of enlarging tumor cysts. Brachytherapy has commonly been used as an adjunct to the standard treatment of surgery and external-beam radiation (EBR). Historically, multimodal treatment, including EBR, has shown tumor control rates as high as 70% at 10 years after treatment. However, EBR is associated with significant long-term risks, including visual deficits, endocrine dysfunction, and cognitive decline. Theoretically, brachytherapy may provide focused local radiation that controls or shrinks a symptomatic cyst without exposing the patient to the risks of EBR. For this study, the authors reviewed their experiences with craniopharyngioma patients treated with P32 brachytherapy as the primary treatment without EBR. The authors reviewed these patients' records to evaluate whether this strategy effectively controls tumor growth, thus avoiding the need for further surgery or EBR. METHODS The authors performed a retrospective review of pediatric patients treated for craniopharyngioma between 1997 and 2004. This was the time period during which the authors' institution had a relatively high use of P32 for treatment of cystic craniopharyngioma. All patients who had surgery and injection of P32 without EBR were identified. The patient records were analyzed for complications, cyst control, need for further surgery, and need for future EBR. RESULTS Thirty-eight patients were treated for craniopharyngioma during the study period. Nine patients (23.7%) were identified who had surgery (resection or biopsy) with P32 brachytherapy but without initial EBR. These 9 patients represented the study group. For 1 patient (11.1%), there was a complication with the brachytherapy procedure. Five patients (55.5%) required subsequent surgery. Seven patients (77.7%) required subsequent EBR for tumor growth. The mean time between the injection of P32 and subsequent treatment was 1.67 ± 1.50 years (mean ± SD). CONCLUSIONS In this small but focused population, P32 treatment provided limited local control for cyst growth. Brachytherapy alone did not reliably avert the need for subsequent surgery or EBR.

show abstract

Evaluation of postoperative intratumoral injection of bleomycin for craniopharyngioma in children

Cited by 122 publications

References 12 publications

Tumors of the skull base in children: review of tumor types and management strategies

Tumors of the skull base in children: review of tumor types and management strategies

Intracystic treatments for craniopharyngioma

Efficacy of phosphorus-32 brachytherapy without external-beam radiation for long-term tumor control in patients with craniopharyngioma

Contact Info

Product

Resources

About